Market Closed - Nasdaq 04:30:00 2024-04-15 pm EDT 5-day change 1st Jan Change
5.67 USD -1.39% Intraday chart for Pluri Inc. +1.25% +22.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care MT
Pluri Receives US Patent for Immune Cell Expansion MT
Pluri Inc. Unveils A Novel Method for Expansion of Immune Cells Using Proprietary Technology CI
Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing CI
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation CI
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis CI
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division CI
Pluri Inc. Launches New Business Division Offering Cell Therapy Manufacturing Services as Contract Development and Manufacturing Organization: PluriCDMO CI
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction CI
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation CI
Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors CI
Pluri Signs Contract With US Institute of Allergy and Infectious Diseases to Develop Radiation Syndrome Treatment MT
Pluri Inc. Signs A Three Year $4.2 Million Contract with the U.S. National Institute of Allergy and Infectious Diseases CI
Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Pluri Inc. announced that it has received $8.469323 million in funding CI
Pluri Inc. announced that it expects to receive $8.170972 million in funding CI
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Pluri Inc.(NasdaqGM:PLUR) dropped from S&P Global BMI Index CI
Chart Pluri Inc.
More charts
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
More about the company
  1. Stock Market
  2. Equities
  3. PLUR Stock
  4. News Pluri Inc.
  5. Pluristem Therapeutics : Plans to Offer 4.8 Million Shares to Institutional Investors